Clinical trial
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase…
NCT00429949 · Washington University School of Medicine, Other · Completed
Key facts
| NCT number | NCT00429949 |
|---|---|
| Title | A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma |
| Official title | A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma |
| Lead sponsor | Washington University School of Medicine, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Relapsed, Refractory or Plateau Phase Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 21 |
| Start date | Jan 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Feb 1, 2007 |
| Last update posted | Aug 29, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: